Earnings Call · Q2 FY2022·2022-08-12

Q2 22EPS +18.18%·Rev n/aQ1 22EPS n/a·Rev n/aQ4 21EPS n/a·Rev n/aQ3 21EPS n/a·Rev n/a⚠ consensus missing

Starling Oncology, Inc. TOI

Mark Hueppelsheuser — General Counsel

Brad Hively — Chief Executive Officer

Mihir Shah — Chief Financial Officer

−12.0%1d on move date−13.7% vs SPY3d−8.6%5d−5.4%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more TOI calls or request research access.

More TOI calls Browse calls Request research access